Develops drugs for metabolic and endocrine disorders.
Jun 2026Revenue $0.00/yrExpenses $560M/yr
No trendCash runway ≈ 1.2 years from Jun 2026
Figures by year
When will Viking Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $560M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $393M | −$393M |
| Dec 2024 | $0.00 | $151M | −$151M |
| Dec 2023 | $0.00 | $101M | −$101M |
| Dec 2022 | $0.00 | $70.4M | −$70.4M |
| Dec 2021 | $0.00 | $55.7M | −$55.7M |
| Dec 2020 | $0.00 | $42.7M | −$42.7M |
| Dec 2019 | $0.00 | $32.7M | −$32.7M |
| Dec 2018 | $0.00 | $26.2M | −$26.2M |
| Dec 2017 | $0.00 | $19.1M | −$19.1M |
| Dec 2016 | $0.00 | $13.8M | −$13.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.